Skip to main content

Cabergoline Disease Interactions

There are 5 disease interactions with cabergoline:

Major

Cabergoline (applies to cabergoline) cardiac valvular disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Valvular Heart Disease

Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline. This drug is contraindicated in patients with history of cardiac valvular disorder. All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..

Major

Cabergoline (applies to cabergoline) hypertension

Major Potential Hazard, High plausibility.

The use of cabergoline is contraindicated in patients with uncontrolled hypertension. Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.

References

  1. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.
Major

Dopamine agonists (applies to cabergoline) hypotension

Major Potential Hazard, Moderate plausibility.

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.

References

  1. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol 30 (1990): 194-9
  3. Hoehn MM "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol 32 (1975): 50-1
  4. "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.
  5. "Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.
  6. "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim, Ridgefield, CT.
View all 6 references
Major

Dopaminergic antiparkinson agents (applies to cabergoline) psychosis

Major Potential Hazard, Moderate plausibility.

Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.

Moderate

Cabergoline (applies to cabergoline) hepatic dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Liver Disease

Cabergoline is extensively metabolized by the liver primarily by hydrolysis. Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction. Careful monitoring should be exercised.

References

  1. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.

Cabergoline drug interactions

There are 142 drug interactions with cabergoline

Cabergoline alcohol/food interactions

There are 2 alcohol/food interactions with cabergoline

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.